Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral P2Y12 platelet inhibitor used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Treatment in patients with a history of myocardial infarction (MI) to reduce the rate of cardiovascular death, MI, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or longer if tolerated and indicated.
* **Following ACS and PCI:** Dosing may be reduced to 60 mg orally twice daily for up to 36 months in specific patient populations based on clinical judgment and local protocols.
## Pediatric Dosing
* The safety and efficacy of ticagrelor in pediatric patients have not been established.
## Dose Adjustments
* No specific dose adjustments are recommended for hepatic or renal impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Concomitant use with strong CYP3A4 inhibitors.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bruising, bleeding (including major and minor).
* **Serious:** Major bleeding, intracranial hemorrhage, life-threatening bleeding.
* **Other:** Ventricular pauses, bradycardia.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid coadministration with potent CYP3A4 substrates (e.g., simvastatin, lovastatin) due to increased exposure.
* **CYP3A4 Inhibitors/Inducers:** Avoid coadministration with strong CYP3A4 inhibitors and inducers.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Monitor closely.
* **Aspirin:** Concomitant use with aspirin is generally recommended, but higher doses of aspirin may decrease the efficacy of ticagrelor.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel or prasugrel.
* Dyspnea is a common side effect and is generally not an indicator of underlying cardiac or pulmonary disease.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If interruption is necessary, consider the risks and benefits.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
